Publication:
Identifying and treating subclinical thyroid dysfunction in pregnancy: emerging controversies

No Thumbnail Available
Date
2018-01-01
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Bioscientifica ltd
Export
Research Projects
Organizational Units
Journal Issue
Abstract
Thyroid hormones are essential for an adequate growth and development of the fetus. In addition to the classical association between maternal hypothyroidism and neurological impairment in the progeny, other adverse reproductive events have been associated with maternal thyroid dysfunction including infertility, miscarriage and preterm delivery. Although all scientific societies endorse the treatment of overt hypothyroidism; the management and/or treatment of subclinical hypothyroidism, hypothyroxinemia or antithyroid antibody-positive women should be considered with caution. Important trials have found no clear benefit of treatment of subclinical hypothyroidism in terms of cognitive outcomes; however, other interventional studies appear to reduce some of the obstetric and perinatal complications. As a result, the dilemma between universal screening or selective screening of women at high risk of thyroid dysfunction during pregnancy remains unresolved. Despite this, levothyroxine is also now regularly prescribed by gynaecologists and centres for reproductive medicine. In this context, there is increasing concern regarding the risk of over diagnosis and subsequent potential overtreatment. Taken together, we need to reconsider how thyroid dysfunction should be identified in pregnant women and highlight the arguments for and against the use of levothyroxine in obstetric practices. Our main findings: the mismatch between the guidelines recommendations and the use of LT4 in clinical settings as well as the disparity of criteria between scientific societies from different medical specialties. In conclusion, it is essential to reach agreements between both endocrinologists and obstetricians.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Assisted reproduction technologies, Antibody-positive women, In-vitro fertilization, Levothyroxine treatment, Recurrent miscarriage, Preterm delivery, 1st trimester, Peroxidase antibody, Risk-factor, Tsh levels
Citation